Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гломерулярные болезни: иммуноглоболин А-нефропатия

Список литературы

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139-274. https://kdigo.org/wp-content/uploads/2017/02/КDIGO-2012-GN­ Guideline-Engli sh.pdf
  2. Нефрология. Клинические рекомендации. По ред. Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГОЭТАР-Медиа, 2016
  3. Schena FP, Nistor 1. Epidemiology of IgA Nephropathy: А Global Perspective. Semin Nephrol 2018;38:435-442. doi: 10.1016/j .semnephrol.2018.05.013
  4. Reily С, Ueda Н, Huang ZQ et al. Cellular Signaling and Production of Galactose­ Deficient IgAl in IgA Nephropathy, an Autoimmune Disease. Journal of Immunology Research 2014(2):197548. doi: 10.1155/2014/197548
  5. Hiki У, Odani Н, Takahashi М et al. Mass spectrometry proves under-O-glycosylation of glomerular IgAl in IgA nephropathy. Kidney Int 2001;59(3): 1077-1085. doi: 10.1046/j.1523-1755.2001.0590031077.х
  6. Tomana М, Novak J, Julian В et al. Circulating immune complexes in IgA nephropathy consist of IgAl with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104(1):73-81. doi: 10.1172/JCI5535
  7. Boyaka PN. Inducing Mucosal IgA: А Challenge for Vaccine Adjuvants and Delivery Systems. J Immunol 2017;199:9-16. doi: 10.4049/jimmunol.1601775
  8. Muto М, Manfroi В, Suzuki Н et al. Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of а Proliferation-Inducing Ligand Ьу Tonsillar Germinal Center В Cells in IgA Nephropathy. J Ат Soc Nephrol 2017;28(4):1227-1238. doi: 10.168 l/ASN.2016050496
  9. Robert Т, Berthelot L, Cambier А et al. Molecular Insights into the Pathogenesis of IgA Nephropathy. TrendMol Med20l5;12:762-775. doi: 10.1016/j.molmed.2015.10.003
  10. Ben Mkaddem S, Benhamou М, Monteiro RC. Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools. Front Immunol 2019;10:1-12. doi: 10.3389/fimmu.2019.00811
  11. Novak J, Julian ВА, Tomana М et al. IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA Nephropathy. Semin Nephrol 2008;28(1):78-87. doi: 10.1016/j.semnephrol.2007.10.009
  12. Wyatt RJ, Julian ВА. IgA Nephropathy. N Engl J Med 2013;368:2402-2414. doi: 10.1056/NEJМral206793
  13. Novak J, Tomana М, Matousovic К et al. IgAl-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005;67:504-513. doi: 10. l l l l/j.1523-l 755.2005.67107.x
  14. Kiryluk К, Li У, Sanna-Cherchi S et al. Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 2012;8(6):е1002765. doi: 10.1371/journal.pgen.1002765
  15. Moriyama Т, Tanaka К, Iwasaki С et al. Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at а Single Center in Japan. PLOS ONE 2014;9(3):е91756. doi: 10.1371/journal.pone.0091756
  16. Lee Н, Kim DK, Oh КН et al. Mortality oflgA Nephropathy Patients: А Single Center in Korea. Experience over 30 Years. PLoS ONE 2012;7(12):е51225. doi: 10.1371/journal.pone.0051225
  17. Le W, Liang S, Hu У et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from а cohort of 1155 cases in а Chinese adult population. Nephrol Dial Transplant 2012;27: 1479-1485. doi: 10.1093/ndt/gfr527
  18. Сорро R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA­ nephropathy in cohorts with different presentations and treatments. Kidney Int 2014;86:828-836. doi: 10.1038/ki.2014.63
  19. Добронравов ВА, Мужецкая ТО, Лин ДИ, Кочоян ЗШ. Иммуноглобулин А­ нефропатия в российской популяции: клинико-морфологическая презентация и отдаленный прогноз. Нефрология 2019;23(6):45-60. doi: 10.36485/1561-6274-2019- 236-45-60
  20. Сурсякова КИ, Сафьянова ТВ. Некоторые эпидемиологические особенности заболеваемости гломерулярными и тубулоинтерстициальными болезнями почек и инфекциями мочевыводящих путей в Алтайском крае. Экспериментальная и клиническая урология 2017;4:6-11
  21. Уео SC, Goh SM, Barratt J. Is immunoglobulin А nephropathy different in different ethnic populations? Nephrology (Carlton) 2019;24(9):885-895. doi: 10.1111/nep.13592
  22. Chang JН, Kim DK, Kim НW et al. Changing prevalence of glomerular diseases in Korean adults: а review of 20 years of experience. Nephrol Dial Transplant 2009;24(8):2406-2410. doi: 10.1093/ndt/gfp091
  23. Андрусев АМ, Томилина НА, Перегудова НГ, Шинкарев МБ. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. http://nephro.ru/index.php?r=site/pageView&id=298%20,%20journal.nephro.ru/index.ph p?r=journal/pageView&id=298
  24. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  25. Levey AS, Stevens LA, Schmid СН et al. А new equation to estimate glomerular filtration rate. Апп Intern Med 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9- 200905050-00006
  26. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Ат J Kidney Dis 2010;55(4):622-7. doi: 10.1053/j .ajkd.2010.02.337
  27. Cattran DC, Сорро R, Cook НТ et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. А Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Kidney Int 2009;76(5): 534-545. doi: 10.1038/ki.2014.63
  28. Trimarchi Н, Barratt J, Cattran DC et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification oflgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 2017;91(5):1014-1021. doi: 10.1016/j .kint.2017.02.003
  29. Barbour SJ, Сорро R, Zhang Н et al. Evaluating а New International Risk­ Prediction Tool in IgA Nephropathy. JАМА Intern Med 2019;179(7):942-952. doi: 1О.1001/j amainternmed.2019.0600
  30. Wang М, Lv J, Zhang Х et al. Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy. Kidney Int Rep 2019;5(2): 165-172. doi: 10.1016/j .ekir.2019.10.012
  31. Saha МК, Julian ВА, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int 2018;94(4):674-681. doi: 10.1016/j.kint.2018.02.030
  32. Liu LL, Wang LN, Jiang У et al. Tonsillectomy for IgA nephropathy: а meta-analysis. Ат J Kidney Dis 2015;65(1):80-7. doi: 10.1053/j.ajkd.2014.06.036
  33. Duan J, Liu D, Duan G, Liu Z. Long-term efficacy of tonsillectomy as а treatment in patients with IgA nephropathy: а meta-analysis. Int Urol Nephrol 2017;49(1): 103-112. doi: 10.1007/sl 1255-016-1432-7
  34. Inker LA, Mondal Н, Greene Т et al. Early Change in Urine Protein as а Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. Ат J Kidney Dis 2016;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042
  35. Thompson А, Carroll К, А Inker L et al. Proteinuria Reduction as а Surrogate End Point in Trials of IgA Nephropathy. Clin J Ат Soc Nephrol 2019;14(3):469-481. doi: 10.2215/CJN.08600718
  36. Offringa М, Benbassat J. The value of urinary red cell shape in the diagnosis of glomerular and post-glomerular haematuria. А meta-analysis. Postgrad Med J 1992;68(802):648-54. doi: 10.1136/pgmj .68.802.648
  37. Bi TD, Zheng JN, Zhang JX et al. Serum complement С4 is an important prognostic factor for IgA nephropathy: а retrospective study. ВМС Nephrol 2019;20(1):244. doi: 10. l 186/sl2882-019-1420-0
  38. Рап М, Zhou Q, Zheng S et al. Serum С3/С4 ratio is а novel predictor of renal prognosis in patients with IgA nephropathy: а retrospective study. Immunol Res 2018;66(3):381- 391. doi: 10.1007/sl2026-018-8995-6
  39. Рап М, Zhang J, Li Z et al. Increased С4 and decreased С3 levels are associated with а poor prognosis in patients with immunoglobulin А nephropathy: а retrospective study. ВМС Nephrol 2017;18(1):231. doi: 10. l 186/sl2882-0l 7-0658-7
  40. Zhang У, Duan SW, Chen Р et al. Relationship between serum С3/С4 ratio and prognosis of immunoglobulin А nephropathy based on propensity score matching. Chin Med J (Engl) 2020;133(6):631-637. doi: 10.1097/СМ9.ООООООООООООО674
  41. Zhang J, Wang С, Tang У et al. Serum immunoglobulin А/С3 ratio predicts progression of immunoglobulin А nephropathy. Nephrology (Carlton) 2013;18(2):125-31. doi: 10.1111/nep.12010
  42. Lv J, Shi S, Xu D et al. Evaluation of the Oxford Classification of IgA nephropathy: а systematic review and meta-analysis. Ат J Kidney Dis 2013;62(5):891-9. doi: 10.1053/j .ajkd.2013.04.021
  43. Shao Х, Li В, Сао L et al. Evaluation of crescent formation as а predictive marker in immunoglobulin А nephropathy: а systematic review and meta-analysis. Oncotarget 2017;8(28):46436-46448. doi: 10.18632/oncotarget.l 7502
  44. Nakamoto У, Asano У, Dohi К et al. Primary IgA glomerulonephritis and Schбnlein­ Henoch purpura nephritis: Clinicopathological and immunohistological characteristics. Q J Med 1978;47(188):495-516
  45. Yang Р, Zou Н, Xiao В, Xu G. Comparative Efficacy and Safety of Therapies in IgA Nephropathy: А Network Meta-analysis of Randomized Controlled Trials. Kidney Int Rep 2018;3(4):794-803. doi: 10.1016/j.ekir.2018.03.006
  46. Zhao У, Fan Н, Вао ВУ. Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: А Meta-Analysis of Randomized Controlled Trials. Iran J PuЬlic Health 2019;48(9): 1577-1588
  47. Ji У, Yang К, Xiao В, Lin J et al. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor Ыocker therapy for IgA nephropathy: А meta-analysis of randomized controlled trials. J Cell Biochem 2019;120(3):3689-3695. doi: 10.1002/jcb.27648
  48. Han S, Уао Т, Lu У et al. Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: А Network Meta-Analysis. Front Pharmacol 2021;11:539545. doi: 10.3389/fphar.2020.539545
  49. Liu LJ, Yang YZ, Shi SF et al. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: А Randomized Controlled Trial. Ат J Kidney Dis 2019;74(1): 15-22. doi: 10.1053/j .ajkd.2019.01.026
  50. Eljaaly К, Alireza КН, Alshehri S, Al-Tawfiq JA. Hydroxychloroquine safety: А meta­ analysis of randomized controlled trials. Travel Med Infect Dis 2020;36:101812. doi: 10.1016/j .tmaid.2020.101812
  51. Rollino С, Vischini G, Сорро R. IgA nephropathy and infections. J Nephrol 2016;29(4):463-8. doi: 10.1007/s40620-016-0265-x
  52. Rehnberg J, Symreng А, Ludvigsson JF, Emilsson L. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: А Swedish Population-Based Cohort Study. J Ат Soc Nephrol 2021;32(2):411-423. doi: 10.1681/ASN.2020060848
  53. Liu XZ, Zhang УМ, Jia NY, Zhang Н. Helicobacter pylori infection is associated with elevated galactose-deficient IgAl in IgA nephropathy. Ren Fail 2020;42(1):539-546. doi: 10.1080/0886022Х.2020.1772295
  54. Pipili С, Michopoulos S, Sotiropoulou М et al. Is there any association between IgA nephropathy, Crohn's disease and Helicobacter pylori infection? Ren Fail 2012;34(4):506-9. doi: 10.3109/0886022Х.2011.653774
  55. Jiang J, Wang ХХ, Shen РС et al. Clinical investigation of mucosal immune system in IgA nephropathy patients. J DalianMed Univ 2016;38:558-61
  56. Chairatana Р, Nolan ЕМ. Defensins, lectins, mucins, and secretory immunoglobulin а: microbe-binding biomolecules that contribute to mucosal immunity in the human gut. Crit Rev Biochem Mol Biol 2017;52:45-56. doi: 10.1080/10409238.2016.1243654
  57. Russell MW, Mestecky J, Julian ВА, Galla JН. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986;6:74-86. doi: 10.1007/ВFОО915367
  58. Chang S, Li ХК. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy. Front Med (Lausanne) 2020;7:92. doi: 10.3389/fmed.2020.00092
  59. Natale Р, Palmer SC, Ruospo М et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2020;3(3):CD003965. doi: 10.1002/14651858
  60. Yang Р, Wang Q, Xie С et al. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis. Kidney Blood Press Res 2018;43(6):1890-1897. doi: 10.1159/000496000
  61. Тап J, Dong L, Уе D et al. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: А network meta-analysis. Sci Rep 2020;10(1):6062. doi: 10.1038/s41598-020-63l 70-w
  62. Zhang Z, Yang У, Jiang SM, Li WG. Efficacy and safety of immunosuppressive treatment in IgA nephropathy: а meta-analysis of randomized controlled trials. ВМС Nephrol 2019;20(1):333. doi: 10. l 186/sl2882-019-1519-3
  63. Tian L, Shao Х, Xie У et al. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: а meta-analysis of controlled clinical trials with more than 5-year follow-up. Expert Opin Pharmacother 2015;16(8):1137-47. doi: 10.1517/14656566.2015.1038238
  64. Avino LJ, Naylor SM, Roecker АМ. Pneumocystis jirovecii Pneumonia in the Non-HIV- Infected Population. Апп Pharmacother 2016;50(8):673-9. doi: 10.1177/1060028016650107
  65. Мельниченко ГА, Белая ЖЕ, Рожинская ЛЯ и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии 2017;63(6):392-426. doi: 10.14341/рrоЫ2017636392-426
  66. Добронравов ВА, Кочоян ЗШ, Мужецкая ТО, Лин ДИ. Анализ эффективности терапии иммуноглобулин А-нефропатии. Терапевтический архив 2020;92(6):23-32. doi: 1О.26442/00403660.2020.06.000669
  67. Adachi М, Sato М, Miyazaki М et al. Steroid pulse therapy transiently destroys the discriminative histological structure of tonsils in IgA nephropathy: Tonsillectomy should Ье performed before or just after steroid pulse therapy. Auris Nasus Larynx 2018;45(6): 1206-1213. doi: 10.1016/j.anl.2018.04.009
  68. Zheng JN, Bi TD, Zhu LB, Liu LL. Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials. Ехр Ther Med 2018;16(3):1882-1890. doi: 10.3892/etm.2018.6418
  69. Liu У, Xiao J, Shi Х et al. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: А meta-analysis. Ехр Ther Med 2016;11(1):49-56. doi: 10.3892/etm.2015.2860. Erratum in: Ехр Ther Med 2019;17(4):2877
  70. Zheng J, Gong Х, Wu Z. Immunosuppressive agents in the treatment of IgA nephropathy: А meta-analysis of clinical randomized controlled literature. Niger J Clin Pract 2020;23(4):437-449. doi: 10.4103/njcp.njcp_l 12_18
  71. Ма F, Yang Х, Zhou М et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. J Nephrol 2020;33(6): 1241-1250. doi: 10.1007/s40620-020-00752-x
  72. Du В, Jia У, Zhou W, Min Х, Miao L, Cui W. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis. ВМС Nephrol 2017;18(1):245. doi: 10. l 186/sl2882-0l 7-0647-x
  73. Chen У, Li У, Yang S, Li У, Liang М. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: а systematic review. ВМС Nephrol 2014;15:193. doi: 10.1186/1471-2369-15-193
  74. Schena FP, Montenegro М, Scivittaro V. Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant 1990;5 Suppl 1:47-52. doi: 10.1093/ndt/5.suppl_l.47
  75. Sarcina С, Tinelli С, Ferrario F et al. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. Clin J Ат Soc Nephrol 2016;11(6):973-81. doi: 10.2215/CJN.02300215
  76. Liu Т, Wang У, Мао Н et al. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: А network meta-analysis. Medicine (Baltimore) 2021;100(8):е24541. doi: 1О.1097/МD.0000000000024541
  77. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Ат Soc Nephrol 2002;13(1):142-8
  78. Mclntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001;56(3):193-8
  79. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003;18(7):1321-1329
  80. Ramachandran R, Doddi Р, Nandakrishna В et al. Combination of pulse cyclophosphamide and steroids in crescentic IgA nephropathy. Int Urol Nephrol 2015;47(11):1917-1918. doi: 10.1007/sl 1255-015-1076-z
  81. Liu Х, Dewei D, Sun S et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther 2014;52(2):95-102. doi: 10.5414/СР201887
  82. Hernandez-Rodriguez J, Carbonell С, Mir6n-Canelo JA et al. Rituximab treatment for IgA vasculitis: А systematic review. Autoimmun Rev 2020;19(4):102490. doi: 10.1016/j.autrev.2020.102490
  83. Obri ca В, tefan G, Gherghiceanu М et al. "Associated" or "Secondary" IgA nephropathy? An outcome analysis. PLoS Опе 2019;14(8):е0221014. doi: 10.1371/journal.pone.0221014
  84. Острое повреждение почек (ОПП). Клинические https://rusnephrology.org/wp-content/uploads/2020/12/АКI_final.pdf

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*